Sienna Biopharmaceuticals, Inc.
SNNAQ · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,820 | $5,084 | $7,093 | $10,774 |
| G&A Expenses | $5,021 | $2,643 | $8,746 | $8,995 |
| SG&A Expenses | $5,021 | $2,643 | $8,746 | $8,995 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8,841 | $7,727 | $15,839 | $19,769 |
| Operating Income | -$6,036 | -$7,727 | -$15,839 | -$19,769 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $253 | -$537 | -$543 | $434 |
| Pre-Tax Income | -$8,588 | -$8,264 | -$16,382 | -$19,335 |
| Tax Expense | -$4,618 | $0 | $0 | -$40 |
| Net Income | -$3,970 | -$8,264 | -$16,382 | -$19,295 |
| % Margin | – | – | – | – |
| EPS | -0.13 | -0.27 | -0.67 | -0.93 |
| % Growth | 51.9% | 59.7% | 28% | – |
| EPS Diluted | -0.13 | -0.27 | -0.67 | -0.93 |
| Weighted Avg Shares Out | 30,726 | 30,354 | 24,606 | 20,805 |
| Weighted Avg Shares Out Dil | 30,726 | 30,354 | 24,606 | 20,805 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $36 | $37 | $39 | $40 |
| EBITDA | -$8,805 | -$7,690 | -$15,800 | -$19,729 |
| % Margin | – | – | – | – |